Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.87 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.87 |
| ▸ | MAPT | P10636 | 2/20 | 0.87 |
| ▸ | MEN1 | O00255 | 2/20 | 0.87 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.87 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.87 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.87 |
| ▸ | SQLE | Q14534 | 5/20 | 0.63 |
| ▸ | FNTA | P49354 | 2/20 | 0.58 |
| ▸ | FNTB | P49356 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Geraniol SCHEMBL5576775 | 0.98 | KMT2A (0.86) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| Geraniol SCHEMBL5576765 | 0.98 | KMT2A (0.86) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| Farnesol SCHEMBL509427 | 0.94 | KMT2A (0.83) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| Farnesol SCHEMBL29087994 | 0.94 | KMT2A (0.83) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| Geranylgeraniol SCHEMBL1573864 | 0.94 | KMT2A (0.83) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| Geranylgeraniol SCHEMBL23814969 | 0.93 | KMT2A (1.00) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| Geranylgeraniol SCHEMBL16664300 | 0.93 | KMT2A (1.00) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL7944378 | 0.93 | KMT2A (1.00) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL4717874 | 0.93 | KMT2A (1.00) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| Geranylgeraniol SCHEMBL156882 | 0.93 | KMT2A (1.00) | KMT2AALOX15MAPTMEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1910399-A4 | NOVEL INTERMEDIATES, PROCESS FOR THEIR PREPARATION AND PROCESS FOR THE PREPARATION OF COQ10 EMPLOYING THE SAID NOVEL INTERMEDIATES | NICHOLAS PIRAMAL INDIA LTD (IN) | 2009-01-21 | — | — | EP | disclosed |
| US-20080200702-A1 | Novel Intermediates, Process for Their Preparation and Process for the Preparation of Coq10 Employing the Said Novel Intermediates | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2008-08-21 | — | — | US | disclosed |
| EP-1910399-A2 | NOVEL INTERMEDIATES, PROCESS FOR THEIR PREPARATION AND PROCESS FOR THE PREPARATION OF COQ10 EMPLOYING THE SAID NOVEL INTERMEDIATES | Nicholas Piramal India Limited (IN) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007004092-A2 | NOVEL INTERMEDIATES, PROCESS FOR THEIR PREPARATION AND PROCESS FOR THE PREPARATION OF COQ10 EMPLOYING THE SAID NOVEL INTERMEDIATES | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200702-A1 | Novel Intermediates, Process for Their Preparation and Process for the Preparation of Coq10 Employing the Said Novel Intermediates | NDUFA10, COQ8A, NDUFB10 | KMT2A 1327/4885ALOX15 286/4885MAPT 2750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.